Viropharma Extends Enterprise Contract with Medidata Solutions

Medidata Solutions

announced that Exton, Pa.-based ViroPharma Incorporated has extended its agreement to use the

Medidata Rave

electronic data capture (EDC) and clinical data management (CDM) platform for another multi-year period.

ViroPharma is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma currently focuses its drug development activities in diseases including hereditary angioedema (HAE), also known as C1 inhibitor deficiency and

C. difficile.

ViroPharma selected Rave initially in 2003 as an enterprise-wide EDC system based on its ability to handle large, complex, global studies and its collaboration-enabling data collection, management and reporting capabilities. Since then, ViroPharma has used Medidata Rave in all Phase I–IV clinical studies, covering a broad range of patients, countries and sites.